This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Roivant Sciences Ltd. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 08:40 AM
Transcript : Roivant Sciences Ltd. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 11:30 AM
Roivant Sciences Ltd. Reports Earnings Results for the Full Year Ended March 31, 2024 CI
Transcript : Roivant Sciences Ltd., Q4 2024 Earnings Call, May 30, 2024
Roivant Sciences' Fiscal Q4 Net Loss Widens, Revenue Rises MT
Futures Decline Pre-Bell as Traders Await Key Economic Reports; Asia Down, Europe Rises MT
Roivant Sciences Ltd. Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 CI
Transcript : Roivant Sciences Ltd. Presents at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ, May-20-2024 09:00 AM
Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit MT
Moderna Suffers Setback in Lawsuit by Arbutus MT
Moderna shares fall after judge sides with Arbutus in patent fight RE
Deutsche Bank Raises Roivant Sciences' Price Target to $15 From $14, Maintains Buy Rating MT
Goldman Sachs Raises Roivant Sciences' Price Target to $18 From $16, Maintains Buy Rating MT
HC Wainwright Raises Roivant Sciences Price Target to $18 From $17, Maintains Buy Rating MT
Roivant Sciences Says Study of Potential Uveitis Treatment Meets Endpoints; Launches Stock Repurchase; Shares Rise MT
Transcript : Roivant Sciences Ltd. - Special Call
Roivant Sciences Ltd. announces an Equity Buyback for $1,500 million worth of its shares. CI
Roivant's anti-inflammatory drug succeeds in mid-stage study RE
Roivant and Priovant Therapeutics Announce Positive Results from the Phase 2 Study for Brepocitinib in NIU CI
Roivant Sciences Ltd. authorizes a Buyback Plan. CI
Roivant Sciences Ltd.(NasdaqGS:ROIV) added to S&P 1000 CI
Roivant Sciences Ltd.(NasdaqGS:ROIV) added to S&P 400 - Biotechnology CI
Roivant Sciences Ltd.(NasdaqGS:ROIV) added to S&P 400 Health Care CI
Roivant Sciences Ltd.(NasdaqGS:ROIV) added to S&P Composite 1500 CI
Roivant Sciences Ltd.(NasdaqGS:ROIV) added to S&P 400 CI
Chart Roivant Sciences Ltd.
More charts
Roivant Sciences Ltd. is a commercial-stage biopharmaceutical company that seeks to improve the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline is focused on inflammation and immunology and includes VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; batoclimab and IMVT-1402, fully human monoclonal antibodies targeting the neonatal Fc receptor in development across several IgG-mediated autoimmune indications; and brepocitinib, a TYK2/JAK1 inhibitor in late stage development for dermatomyositis, non-infectious uveitis, and other autoimmune conditions, in addition to other clinical-stage molecules. It advances its pipeline by creating nimble subsidiaries or Vants to develop and commercialize its medicines and technologies. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
10.57 USD
Average target price
16.78 USD
Spread / Average Target
+58.73%
Consensus
  1. Stock Market
  2. Equities
  3. ROIV Stock
  4. News Roivant Sciences Ltd.
  5. Roivant Sciences Says Study of Potential Uveitis Treatment Meets Endpoints; Launches Stock Repurchase; Shares Rise